Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 20.70% is 167% above its 5-year average of -30.88%, near the high end of its 5-year range (-56.47%–20.70%).
790.32% above its 12-month average of 2.32%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 2.87%.
RETURN ON ASSETS (ROA)
20.70%
RETURN ON ASSETS (ROA) AVG TTM
2.32%
RETURN ON ASSETS (ROA) AVG 3Y
-24.93%
RETURN ON ASSETS (ROA) AVG 5Y
-30.88%
RETURN ON ASSETS (ROA) AVG 10Y
-71.86%
RETURN ON ASSETS (ROA) AVG 15Y
-136.39%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+790.32%
CURRENT VS 3Y AVG
+183.05%
CURRENT VS 5Y AVG
+167.03%
CURRENT VS 10Y AVG
+128.81%
CURRENT VS 15Y AVG
+115.18%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.75%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
+167.32%
vs the sector median at left
CorMedix Inc.
Market Cap
$566.38M
Return on Assets (ROA)
20.70%
TTM Avg
2.32%
3Y Avg
-24.93%
5Y Avg
-30.88%
Market Cap
$568.20M
Return on Assets (ROA)
-20.89%
TTM Avg
7.49%
3Y Avg
-5.84%
5Y Avg
-12.60%
Market Cap
$560.00M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$574.01M
Return on Assets (ROA)
-59.22%
TTM Avg
-47.88%
3Y Avg
-51.20%
5Y Avg
-67.88%
Market Cap
$550.11M
Return on Assets (ROA)
-42.15%
TTM Avg
-50.20%
3Y Avg
-44.84%
5Y Avg
-47.93%
Market Cap
$552.40M
Return on Assets (ROA)
-37.16%
TTM Avg
-32.95%
3Y Avg
-32.95%
5Y Avg
-32.95%
Market Cap
$550.37M
Return on Assets (ROA)
-124.45%
TTM Avg
-92.75%
3Y Avg
-98.77%
5Y Avg
-98.11%
Market Cap
$587.91M
Return on Assets (ROA)
-7.77%
TTM Avg
-7.89%
3Y Avg
-5.07%
5Y Avg
-5.95%
Market Cap
$540.42M
Return on Assets (ROA)
-30.29%
TTM Avg
-86.87%
3Y Avg
-85.61%
5Y Avg
-77.02%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CorMedix Inc. (CRMD) | $566.38M | 20.70% | 2.32% | -24.93% | -30.88% |
| CytomX Therapeutics, Inc. (CTMX)vs › | $568.20M | -20.89% | 7.49% | -5.84% | -12.60% |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $574.01M | -59.22% | -47.88% | -51.20% | -67.88% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $550.11M | -42.15% | -50.20% | -44.84% | -47.93% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $552.40M | -37.16% | -32.95% | -32.95% | -32.95% |
| Nuvectis Pharma, Inc. (NVCT)vs › | $550.37M | -124.45% | -92.75% | -98.77% | -98.11% |
| OrthoPediatrics Corp. (KIDS)vs › | $587.91M | -7.77% | -7.89% | -5.07% | -5.95% |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $540.42M | -30.29% | -86.87% | -85.61% | -77.02% |
| Delcath Systems, Inc. (DCTH)vs › | $540.26M | 0.39% | -16.14% | -90.03% | -84.55% |
ROA
20.7%
ROE
40.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 19.74% |
| 2024-12-31 | -15.09% |
| 2023-12-31 | -56.47% |
| 2022-12-31 | -47.88% |
| 2021-12-31 | -40.92% |
| 2020-12-31 | -44.67% |
| 2019-12-31 | -55.75% |
| 2018-12-31 | -142.51% |
| 2017-12-31 | -245.36% |
| 2016-12-31 | -112.50% |
| 2015-12-31 | -49.02% |
| 2014-12-31 | -401.22% |
| 2013-12-31 | -307.74% |
| 2012-12-31 | -297.04% |
| 2011-12-31 | -262.57% |
| 2010-12-31 | -123.25% |
| 2009-12-31 | -364.90% |
| 2008-12-31 | -555.25% |
